Arialys Therapeutics
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $58M
Overview
A clinical-stage company creating targeted antibody therapies for severe neuroinflammatory diseases.
NeuroscienceImmunologyAutoimmune Diseases
Technology Platform
A platform for developing CNS-penetrant monoclonal antibodies designed to precisely target inflammatory pathways within the brain.
Funding History
1Total raised:$58M
Grant$58M
Opportunities
Potential to establish a first-in-class treatment for severe neuroinflammatory diseases with no approved therapies.
Risk Factors
Significant biological risk regarding achieving sufficient CNS penetration and demonstrating clinical efficacy in complex, rare diseases.
Competitive Landscape
Competes in the emerging neuro-immunology field against companies like Horizon Therapeutics (now Amgen) and smaller biotechs targeting CNS inflammation.